PHARMACIE CIARAMELLA SEGONDY : revenue, balance sheet and financial ratios

PHARMACIE CIARAMELLA SEGONDY is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-JEAN-DE-VEDAS (34430), this company of category PME shows in 2018 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE CIARAMELLA SEGONDY (SIREN 528404981)
Indicator 2024 2021 2020 2019 2018 2016
Revenue N/C N/C N/C N/C 2 811 241 € 2 227 084 €
Net income 149 538 € 367 178 € 241 594 € 244 704 € 188 854 € 114 677 €
EBITDA N/C N/C N/C N/C 277 550 € 207 546 €
Net margin N/C N/C N/C N/C 6.7% 5.1%

Revenue and income statement

In 2024, PHARMACIE CIARAMELLA SEGONDY generates positive net income of 150 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 115 k€ -> 150 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

149 538 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 30%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 66%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

29.83%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

65.772%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

44.1%

Solvency indicators evolution
PHARMACIE CIARAMELLA SEGONDY

Sector positioning

Debt ratio
29.83 2024
2020
2021
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good

In 2024, the debt ratio of PHARMACIE CIARAMELLA SEGONDY (29.83) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
65.77% 2024
2020
2021
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good +7 pts over 3 years

In 2024, the financial autonomy of PHARMACIE CIARAMELLA SEGONDY (65.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 259.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

259.972

Liquidity indicators evolution
PHARMACIE CIARAMELLA SEGONDY

Sector positioning

Liquidity ratio
259.97 2024
2020
2021
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Good +14 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE CIARAMELLA SEGONDY (259.97) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE CIARAMELLA SEGONDY

Positioning of PHARMACIE CIARAMELLA SEGONDY in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE CIARAMELLA SEGONDY is estimated at 2 087 661 € (range 1 453 814€ - 3 123 260€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1453k€ 2087k€ 3123k€
2 087 661 € Range: 1 453 814€ - 3 123 260€
NAF 5 année 2024

Valuation method used

Net Income Multiple
149 538 € × 14.0x = 2 087 661 €
Range: 1 453 814€ - 3 123 260€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE CIARAMELLA SEGONDY with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE CIARAMELLA SEGONDY

What is the revenue of PHARMACIE CIARAMELLA SEGONDY ?

The revenue of PHARMACIE CIARAMELLA SEGONDY in 2018 is 2.8 M€.

Is PHARMACIE CIARAMELLA SEGONDY profitable?

Yes, PHARMACIE CIARAMELLA SEGONDY generated a net profit of 150 k€ in 2024.

Where is the headquarters of PHARMACIE CIARAMELLA SEGONDY ?

The headquarters of PHARMACIE CIARAMELLA SEGONDY is located in SAINT-JEAN-DE-VEDAS (34430), in the department Herault.

Where to find the tax return of PHARMACIE CIARAMELLA SEGONDY ?

The tax return of PHARMACIE CIARAMELLA SEGONDY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE CIARAMELLA SEGONDY operate?

PHARMACIE CIARAMELLA SEGONDY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.